GlassScriptPhysician profile
Paul Jay Katz
NPI 1497753131
$11,764.85
in general payments reported to CMS, 2019-2025
47 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2021: $593 · 2022: $3,442 · 2023: $2,719 · 2024: $2,404 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,199 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,198.56 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,930.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,857.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,043.69 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $879.42 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $776.02 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $610.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.95 | 2022-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $419.29 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $403.57 | 2021-2023 | Belsomra, Steglatro, Verquvo |
| Pfizer INC. | $390.54 | 2022-2025 | |
| Abbott Laboratories | $264.42 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $258.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $235.09 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $228.82 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $178.82 | 2021-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $156.63 | 2022-2024 | Livalo, Seglentis, Zoryve |
| Esperion Therapeutics, INC. | $154.69 | 2022-2025 | Nexletol |
| Allergan, INC. | $118.53 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $110.00 | 2022 | |
| Corcept Therapeutics | $104.18 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $101.17 | 2021-2023 | |
| C2n Diagnostics, LLC | $100.92 | 2025 | Precivityad2 |
| Nevro Corp. | $70.72 | 2023-2024 | Senza |
| Genzyme Corporation | $70.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $66.97 | 2022-2024 | Rexulti |
| Dexcom, INC. | $63.92 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $60.73 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $53.48 | 2024-2025 | Ibsrela |
| Seqirus USA INC | $49.64 | 2024-2025 | Fluad, Flucelvax |
| Amneal Pharmaceuticals LLC | $46.34 | 2022-2023 | Unithroid |
| Currax Pharmaceuticals LLC | $45.85 | 2022 | |
| Astellas Pharma US INC | $44.10 | 2023 | Veozah |
| Horizon Therapeutics Plc | $43.89 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.54 | 2022-2023 | Qelbree |
| Tris Pharma INC | $35.25 | 2023-2024 | Dyanavel Xr |
| Boston Scientific Corporation | $31.87 | 2025 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.85 | 2024-2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $27.82 | 2024 | Crysvita |
| Idorsia Pharmaceuticals US INC | $27.68 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $24.86 | 2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $23.72 | 2022 | |
| Ironwood Pharmaceuticals, INC | $23.59 | 2023 | Linzess |
| Genentech USA, INC. | $19.02 | 2021 | |
| Almatica Pharma LLC | $17.67 | 2021 | |
| Ascensia Diabetes Care US INC. | $17.45 | 2025 | |
| Lundbeck LLC | $14.38 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.